Chair for Functional Nanomaterials, Institute for Materials Science, Kiel University, Kaiser Str. 2, 24143 Kiel, Germany.
Department of Anatomy, Kiel University, Otto-Hahn-Platz 8, 24118 Kiel, Germany.
ACS Biomater Sci Eng. 2020 Jun 8;6(6):3388-3397. doi: 10.1021/acsbiomaterials.0c00094. Epub 2020 Apr 22.
Localized therapy of the highly malignant brain tumor glioblastoma multiforme (GBM) could help to drastically improve the treatment efficiency and increase the patient's median survival. Here, a macroscopic PDMS matrix composed of interconnected microchannels for tailored drug release and localized GBM therapy is introduced. Based on a simple bottom-up fabrication method using a highly versatile sacrificial template, the presented strategy solves the scaling problem associated with the previously developed microchannel-based drug delivery systems, which were limited to two dimensions due to the commonly employed top-down microfabrication methods. Additionally, tailoring of the microchannel density, the fraction of drug-releasing microchannels and the macroscopic size of the drug delivery systems enabled precise adjustment of the drug release kinetics for more than 10 days. As demonstrated in a long-term GBM model, the release kinetics of the exemplarily chosen GBM drug AT101 could be tailored by variation of the microchannel density and the initial drug concentration, leading to diffusion-controlled AT101 release. Adapting a previously developed GBM treatment plan based on a sequential stimulation with AT101, measured anti-tumorigenic effects of free PDMS-released AT101 were comparable in human GBM cells and demonstrated efficient biological activity of PDMS-released AT101.
局部治疗高度恶性脑肿瘤胶质母细胞瘤(GBM)可以帮助显著提高治疗效率并延长患者的中位生存时间。这里,我们介绍了一种由相互连接的微通道组成的宏观 PDMS 基质,用于定制药物释放和局部 GBM 治疗。基于使用高度通用牺牲模板的简单自下而上的制造方法,所提出的策略解决了与先前开发的基于微通道的药物输送系统相关的缩放问题,由于常用的自上而下的微制造方法,这些系统受到限制只能在二维上进行。此外,通过调整微通道密度、释放药物的微通道比例和药物输送系统的宏观尺寸,可以精确调整药物释放动力学超过 10 天。如在长期 GBM 模型中所示,可以通过改变微通道密度和初始药物浓度来调整所选 GBM 药物 AT101 的释放动力学,从而实现扩散控制的 AT101 释放。根据先前开发的基于 AT101 顺序刺激的 GBM 治疗计划进行调整,测量到的游离 PDMS 释放的 AT101 的抗肿瘤作用在人 GBM 细胞中相当,并且证明了 PDMS 释放的 AT101 的高效生物学活性。